Lymphoproliferative Disorders: Clinical Trials

6509 completed, 2068 recruiting, 1797 unknown, 1692 terminated. 6193 Phase 2, 4560 Phase 1, 1412 Not applicable, 1340 Phase 3, 294 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	6193	Completed 2761, Terminated 873, Recruiting 849, Unknown 643, Active not recruiting 534, Withdrawn 283, Not yet recruiting 213, Suspended 24, Enrolling by invitation 13
Phase 1	4560	Completed 2040, Terminated 724, Recruiting 597, Unknown 452, Active not recruiting 354, Withdrawn 226, Not yet recruiting 132, Suspended 28, Enrolling by invitation 7
Not applicable	1412	Completed 618, Recruiting 248, Unknown 230, Terminated 105, Not yet recruiting 81, Active not recruiting 68, Withdrawn 43, Enrolling by invitation 11, Suspended 8
Phase 3	1340	Completed 645, Unknown 182, Recruiting 174, Active not recruiting 142, Terminated 123, Not yet recruiting 38, Withdrawn 31, Suspended 3, Enrolling by invitation 2
Phase 4	294	Completed 131, Unknown 71, Recruiting 31, Terminated 21, Not yet recruiting 16, Active not recruiting 11, Withdrawn 11, Enrolling by invitation 2
Early Phase 1	280	Unknown 72, Recruiting 66, Completed 45, Not yet recruiting 35, Terminated 30, Active not recruiting 14, Withdrawn 12, Suspended 6

Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma	Not applicable	Not yet recruiting	Lesley A. Jarvis	10	2029-10-31	2026-05-27
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia	Phase 3	Not yet recruiting	Amgen	560	2028-06-30	2026-09-15
Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)	Phase 2	Suspended	Armaceutica, Inc.	200	2028-02-21	2026-10-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors	Not applicable	Not yet recruiting	University of Vermont Medical Center	33	2028-02-01	2026-08-25
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma	Not applicable	Suspended	Medical University of Vienna	45	2027-09-01	2026-10-09
Family-Focused Study to Support Medication for Opioid Use Disorder FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate	Not applicable	Not yet recruiting	University of Wisconsin, Madison	338	2027-08-31	2026-07-07
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2	Not yet recruiting	City of Hope Medical Center	44	2027-08-04	2026-09-10
Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma	Phase 3	Not yet recruiting	Bnai Zion Medical Center	60	2027-08-01	2026-09-30
CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	100	2027-07-01	2026-08-26
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain VR-PAT - Acute Pain, Pediatric ALL	Not applicable	Not yet recruiting	Nationwide Children's Hospital	4	2027-07-01	2026-09-09
Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2027-06-30	2026-08-27
Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-30	2026-08-26
Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL)	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	11	2027-06-01	2026-08-26
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma	Phase 1	Withdrawn	Fred Hutchinson Cancer Center		2027-06-01	2026-09-11
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 2	Recruiting	National Cancer Institute (NCI)	80	2027-05-22	2026-10-23
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL	Phase 2	Not yet recruiting	AbelZeta Inc.	55	2027-05-01	2026-10-15
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia	Phase 2	Recruiting	National Cancer Institute (NCI)	74	2027-04-20	2026-10-26
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma	Phase 1	Not yet recruiting	City of Hope Medical Center	16	2027-04-17	2026-08-11
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma	Phase 1 / Phase 2	Recruiting	National Cancer Institute (NCI)	162	2027-04-12	2026-10-16
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies	Phase 1	Not yet recruiting	GUSTAVO SALGUERO	12	2027-04-01	2026-10-20

Showing 20 of 14473. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3661)  ·  Lymphoma (3016)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2521)  ·  Lymphoma, Non-Hodgkin (2288)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2019)  ·  Lymphoma, Follicular (1875)  ·  Lymphoma, Large B-Cell, Diffuse (1825)  ·  Leukemia (1378)  ·  Hodgkin Disease (1301)  ·  Lymphoma, Mantle-Cell (1210)  ·  Recurrence (1156)  ·  Leukemia, Myeloid, Acute (1031)  ·  Burkitt Lymphoma (974)  ·  Lymphoma, B-Cell, Marginal Zone (864)  ·  Lymphoma, B-Cell (776)

Broader conditions

Immune System Diseases (14393)  ·  Hemic and Lymphatic Diseases (14334)  ·  Immunoproliferative Disorders (14047)  ·  Neoplasms by Histologic Type (13935)  ·  Neoplasms (13305)  ·  Lymphatic Diseases (11493)  ·  Hematologic Diseases (8183)  ·  Lymphoma (5253)  ·  Leukemia, Lymphoid (4252)  ·  Cardiovascular Diseases (4225)  ·  Vascular Diseases (4165)  ·  Paraproteinemias (4115)  ·  Blood Protein Disorders (4056)  ·  Hemorrhagic Disorders (4054)

Interventions

Cyclophosphamide (1580)  ·  Rituximab (1439)  ·  Dexamethasone (1258)  ·  Lenalidomide (802)  ·  Vincristine (696)  ·  Bortezomib (667)  ·  Doxorubicin (635)  ·  Prednisone (591)  ·  fludarabine (555)  ·  Etoposide (546)  ·  Cytarabine (516)  ·  Methotrexate (461)  ·  Melphalan (459)  ·  fludarabine phosphate (435)  ·  Filgrastim (421)

Sponsors

National Cancer Institute (NCI) (620)  ·  M.D. Anderson Cancer Center (451)  ·  Memorial Sloan Kettering Cancer Center (269)  ·  Fred Hutchinson Cancer Center (177)  ·  Celgene (161)  ·  Mayo Clinic (160)  ·  City of Hope Medical Center (155)  ·  Novartis Pharmaceuticals (139)  ·  Hoffmann-La Roche (138)  ·  Dana-Farber Cancer Institute (133)  ·  Institute of Hematology & Blood Diseases Hospital, China (126)  ·  Children's Oncology Group (113)  ·  St. Jude Children's Research Hospital (112)  ·  Janssen Research & Development, LLC (108)  ·  GlaxoSmithKline (106)

Countries

United States (7711)  ·  China (2003)  ·  France (1399)  ·  Italy (1164)  ·  Germany (1005)  ·  United Kingdom (979)  ·  Spain (977)  ·  Canada (972)  ·  Australia (741)  ·  South Korea (559)  ·  Belgium (541)  ·  Poland (483)  ·  Netherlands (474)  ·  Japan (432)  ·  Israel (408)

Results publications

PMID 34515338, PMID 41671463, PMID 35622074, PMID 40135712, PMID 32632956, PMID 32499241, PMID 34398557, PMID 31401903, PMID 40550489, PMID 33357481, PMID 38502198, PMID 39319495, PMID 39563886, PMID 26373676, PMID 31221778, PMID 37022569, PMID 37192741, PMID 37505794, PMID 38620092, PMID 22689675, PMID 23524640, PMID 27209293, PMID 27282998, PMID 31050355, PMID 33242441, PMID 39121442, PMID 40802906, PMID 23065508, PMID 23834234, PMID 29358183, PMID 30125215, PMID 31196847, PMID 32816215, PMID 33218965, PMID 34048072, PMID 35285981, PMID 35787017, PMID 40396505, PMID 40501401, PMID 41429239, PMID 18596230, PMID 19238148, PMID 26182309, PMID 28054442, PMID 28751558, PMID 28803351, PMID 30957581, PMID 31023700, PMID 32770353, PMID 33288485

NIH funding

2023 (166), P30CA033572 (107), P30CA015704 (88), 2017 (78), 2015 (76), P30CA015083 (75), 2016 (72), 2018 (69), 2014 (65), U10CA032102 (62), 2019 (58), 2025 (56), U10CA180820 (53), 2009 (52), P30CA016672 (44)